Doctors have demanded new delivery methods and can now access new technologies to help treat their patients.
BRISBANE, QUEESNLAND, AUSTRALIA, May 13, 2022 /EINPresswire.com/ — MedReleaf Australia. (the “Company” or “MedReleaf”), the company built on more than 50 years of pharmaceutical and healthcare expertise, today announced that it has expanded its product line in Australia with the launch MedReleaf cannabis resin cartridges, a new formulation for the company.
Cannabis resin cartridges are one of the most effective delivery modes for cannabinoids, being a concentrated extract. Doctors have demanded new delivery methods and can now access new technologies to help treat their patients.
The addition of the 2 new cannabis resin cartridges brings the total number of branded finished pharmaceutical products offered by MedReleaf to 24 unique offerings. A wide range of products to match a wide range of conditions treated by Australian doctors.
MedReleaf is also pleased with its progress in the Australian market. With recent market share data published by NostraData, MedReleaf is in 3rd position at the end of 2021.
NostraData – April 2022 Press Release – https://ajp.com.au/news/a-booming-market/
“We are pleased with the market share data recently released by NostraData. The brands held by the first three companies represent 49% of the market. Together with colleagues in the industry, we are working hard to grow the global market and to increase physicians’ acceptance of the therapeutic utility that medical cannabis offers them and their patients. We are especially pleased that so many disadvantaged Australians have access to much cheaper medical cannabis through the MedReleaf franchise program,” said Russell Harding, CEO of MedReleaf Australia.
Nathan Davis, COO of MedReleaf Australia also commented, “Our vision of being the partner of choice for doctors includes having a wide range of good products. We are pleased to have expanded our range with the new MedReleaf Cannabis Resin Cartridges. These are the Next Level for breakthrough symptom relief. Cannabis extract only, produced in Canada under GMP conditions. The cartridges complement other formulations offered by MedReleaf, including dried flowers, oils and soft gels. We will continue to develop products that help patients and their quality. of life.”
About MedReleaf Australia
MedReleaf Australia is a private company established in 2016. MedReleaf is licensed by the federal government’s Office of Drug Control (ODC) to grow and manufacture medical cannabis. MedReleaf also has licenses to import, export and wholesale medical cannabis, backed by over 50 years of pharmaceutical and healthcare expertise, focused on research and development. MedReleaf Australia has an exclusive strategic partnership with Aurora Cannabis Enterprises.
A distinct, low-capital business positioned to take advantage of a rapidly growing market designed to serve the Australian medical industry, including doctors, pharmacists and allied health professionals.
write to us here